Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer

International Journal of Molecular Medicine

Volumn 20, Issue 1, 2007, Pages 21-29

  Simiantonaki, Nektaria ^a,b   Kurzik Dumke, Ursula ^a   Karyofylli, Georgia ^a   Jayasinghe, Caren ^a,b   Michel Schmidt, Romi ^a   Kirkpatrick, Charles James ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

Author keywords

CD14; Colorectal cancer; Lipopolysaccharide; TLR4

Indexed keywords

CD14 ANTIGEN; LIPOPOLYSACCHARIDE; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CARCINOMA; CELL STRAIN CACO 2; COLORECTAL TUMOR; COMPARATIVE STUDY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; PATHOLOGY; RETROSPECTIVE STUDY; TUMOR CELL LINE;

ANTIGENS, CD14; CACO-2 CELLS; CARCINOMA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDES; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TOLL-LIKE RECEPTOR 4;

EID: 34548074523     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.1.21     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Mareel MM, Van Roy FM and Bracke ME: How and when do tumor cells metastasize? Crit Rev Oncog 4: 559-594, 1993.
3. Mantovani A, Bussolino F and Introna M: Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today 18: 231-240, 1997.
4. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
5. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
6. Wilson J and Balkwill F: The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 12: 113-120, 2002.
7. Schletter J, Heine H, Ulmer AJ and Rietschel ET: Molecular mechanisms of endotoxin activity. Arch Microbiol 164: 383-389, 1995.
8. Simiantonaki N, Jayasinghe C and Kirkpatrick CJ: Effect of pro-inflammatory stimuli on tumor cell-mediated induction of endothelial cell adhesion molecules in vitro. Exp Mol Pathol 73: 46-53, 2002.
9. Simiantonaki N, Jayasinghe C and Kirkpatrick CJ: Differential endothelial CAM-expression after stimulation with supernatants of LPS- and cytokine-stimulated HT-29 and ST-ML-12 tumor cells growing as monolayer cultures and multicellular spheroids. Anticancer Res 22: 2641-2649, 2002.
10. Triantafilou M and Triantafilou K: Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 23: 301-304, 2002.
11. Triantafilou M and Triantafilou K: The dynamics of LPS recognition: complex orchestration of multiple receptors. J Endotoxin Res 11: 5-11 2005.
12. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ and Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249: 1431-1433, 1990.
13. Ziegler-Heitbrock HW and Ulevitch RJ: CD14: cell surface receptor and differentiation marker. Immunol Today 14: 121-125, 1993.
14. Sugawara S, Sugiyama A, Nemoto E, Rikiishi H and Takada H: Heterogeneous expression and release of CD14 by human gingival fibroblasts: characterization and CD14-mediated interleukin-8 secretion in response to lipopolysaccharide. Infect Immun 66: 3043-3049, 1998.
15. Jersmann HP, Hii CS, Hodge GL and Ferrante A: Synthesis and surface expression of CD14 by human endothelial cells. Infect Immun 69: 479-485, 2001.
16. Funda DP, Tuckova L, Farre MA, Iwase T, Moro I and Tlaskalova-Hogenova H: CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect Immun 69: 3772-3781, 2001.
17. McCracken VJ, Chun T, Baldeon ME, Ahrne S, Molin G, Mackie RI and Gaskins HR: TNF-alpha sensitizes HT-29 colonic epithelial cells to intestinal lactobacilli. Exp Biol Med 227: 665-670, 2002.
18. Yoshioka T, Morimoto Y, Iwagaki H, Itoh H, Saito S, Kobayashi N, Yagi T and Tanaka N: Bacterial lipopolysaccharide induces transforming growth factor beta and hepatocyte growth factor through toll-like receptor 2 in cultured human colon cancer cells. J Int Med Res 29: 409-420, 2001.
19. Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC and Podolsky DK: Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol 164: 966-972, 2000.
20. Barnes PJ and Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997.
21. Okamoto M, Oshikawa T, Ohe G, Nishikawa H, Furuichi S, Tano T, Moriya Y, Saito M and Sato M: Severe impairment of anti-cancer effect of lipoteichoic acid-related molecule isolated from a penicillin-killed streptococcus pyogenes in toll-like receptor 4-deficient mice. Int Immunopharmacol 1: 1789-1795, 2001.
22. Muzio M, Bosisio D, Polentarutti N, D'amico G, Stoppacciaro A, Mancinelli R, van't Veer C, Penton-Rol G, Ruco LP, Allavena P and Mantovani A: Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164: 5998-6004, 2000.
23. Faure E, Thomas L, Xu H, Medvedev A, Equils O and Arditi M: Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 166: 2018-2024, 2001.
24. Cario E and Podolsky DK: Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68: 7010-7017, 2000.
25. Ortega-Cava CF, Ishihara S, Rumi MA, Kawashima K, Ishimura N, Kazumori H, Udagawa J, Kadowaki Y and Kinoshita Y: Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol 170: 3977-3985, 2003.
26. Bocker U, Yezerskyy O, Feick P, Manigold T, Panja A, Kalina U, Herweck F, Rossol S and Singer MV: Responsiveness of intestinal epithelial cell lines to lipopolysaccharide is correlated with Toll-like receptor 4 but not Toll-like receptor 2 or CD14 expression. Int J Colorectal Dis 18: 25-32, 2003.
27. Schwende H, Fitzke E, Ambs P and Dieter P: Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25- dihydroxyvitamin D3. J Leukoc Biol 59: 555-561, 1996.
28. International Union Against Cancer (UICC): TNM Classification of Malignant Tumors. Sobin LH and Wittekind C (eds). 5th edition, 1997.
29. Zetter BR: Adhesion molecules in tumor metastasis. Semin Cancer Biol 4: 219-229, 1993.
30. Vega VL and De Maio A: Geldanamycin treatment ameliorates the response to LPS in murine macrophages by decreasing CD14 surface expression. Mol Biol Cell 14: 764-773, 2003.
31. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
32. Ishida I, Kubo H, Suzuki S, Suzuki T, Akashi S, Inoue K, Maeda S, Kikuchi H, Sasaki H and Kondo T: Hypoxia diminishes toll-like receptor 4 expression through reactive oxygen species generated by mitochondria in endothelial cells. J Immunol 169: 2069-2075, 2002.
33. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET and Arditi M: Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 167: 1609-1616, 2001.
34. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K and Seya T: Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 68: 6883-6890, 2000.
35. Ahmed SU, Okamoto M, Oshikawa T, Tano T, Sasai A, Kan S, Hiroshima T, Ohue H, Moriya Y, Ryoma Y, Saito M and Sato M: Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunother 27: 432-441, 2004.
36. Okamoto M, Oh-E G, Oshikawa T, Furuichi S, Tano T, Ahmed SU, Akashi S, Miyake K, Takeuchi O, Akira S, Himeno K, Sato M and Ohkubo S: Toll-like receptor 4 mediates the antitumor host response induced by a 55-kilodalton protein isolated from Aeginetia indica L., a parasitic plant. Clin Diagn Lab Immunol 11: 483-495, 2004.
37. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC and Xiong H: Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65: 5009-5014, 2005.
38. Cario E, Brown D, McKee M, Lynch-Devaney K, Gerken G and Podolsky DK: Commersal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmatic compartments in polarized intestinal epithelium. Am J Pathol 160: 165-173, 2002.